Skip to content

Study · Randomized controlled trial · n = 11 · 2017

4 results

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.

Chen WJY, Diamant M, de Boer K, Harms HJ, Robbers LFHJ, van Rossum AC, Kramer MHH, Lammertsma AA, Knaapen P

Cardiovascular diabetology19 May 2017Cited by 21 (Europe PMC)

PMID28526033 (opens in a new tab)PMCIDPMC5438489 (opens in a new tab)DOI10.1186/s12933-017-0549-z (opens in a new tab)PepBankPUB-28526033
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundMultiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored.Methods and resultsTwenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 ± 13%) and 10 controls (LVEF of 59 ± 4%, P 15O]H2O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efficiency, measured using [11C]acetate PET and CMR derived stroke volume, were not different between the groups. Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial. Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine.ConclusionsT2DM patients with LV systolic dysfunction did not have altered myocardial efficiency as compared to healthy controls. Exenatide or insulin glargine had no effects on cardiac function, perfusion or oxidative metabolism. Trial registration NCT00766857.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and LV dysfunction, cardiac function did not change after exenatide.

    In plain wordsIn patients with diabetes and heart dysfunction, cardiac function did not change after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCardiac function
    Study

    n = 11

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine.
    2 context sentences
    Summary · context
    Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored.
    Summary · context
    Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and LV dysfunction, myocardial perfusion did not change after exenatide.

    In plain wordsIn patients with diabetes and heart dysfunction, heart blood supply did not change after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMyocardial perfusion
    Study

    n = 11

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine.
    2 context sentences
    Summary · context
    Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored.
    Summary · context
    Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and LV dysfunction, myocardial metabolism did not change after exenatide.

    In plain wordsIn patients with diabetes and heart dysfunction, heart metabolism did not change after exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMyocardial metabolism
    Study

    n = 11

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine.
    2 context sentences
    Summary · context
    Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored.
    Summary · context
    Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In patients with diabetes and LV dysfunction, systemic metabolic control improved after both exenatide and insulin glargine.

    In plain wordsIn patients with diabetes and heart dysfunction, metabolic control improved with both exenatide and insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedSystemic metabolic control
    Study

    n = 23

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Systemic metabolic control was improved after both treatments, although, no changes in cardiac function, perfusion and metabolism were seen after exenatide or insulin glargine.
    2 context sentences
    Summary · context
    Furthermore, effects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored.
    Summary · context
    Eleven patients in the exenatide group and 12 patients in the insulin glargine group completed the trial.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00766857

Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

Amsterdam UMC, location VUmcn = 27May 2009 to Dec 2012

Type 2 Diabetes Mellitus · Congestive Heart Failure

Trial pageClinicalTrials.govUpdated 9 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.